DENGVAXIA dengue vaccine is FDA approved for use in persons aged six through 16 years with laboratory confirmed history of dengue infection living in dengue endemic areas. Individuals with no prior history of dengue infection, or whose history is not known should not receive DENGVAXIA vaccine. Children younger than six years of age and persons older than aged 16 should not receive the vaccine.
Individuals with a prior history of allergic reaction to a previous dose of DENGVAXIA or to any of its ingredients should not receive the vaccine.
Clinical data is not sufficient to support the safety or effectiveness of DENGVAXIA vaccine in pregnant women, and it is not known whether the vaccine virus can be transmitted from mother to infant.
Persons who are severely immunocompromised due to disease or therapies should not receive DENGVAXIA vaccine.
There is no data to support the use of DENGVAXIA vaccine in persons who do not live in dengue endemic areas who travel to areas where dengue is endemic.
IMPORTANT NOTE: NVIC encourages you to become fully informed about Dengue and the Dengue vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
